Background Renal transplant loss from chronic rejection remains substantial. To increase our understanding of this syndrome we identified risk factors predicting late graft loss with special emphasis on the impact of HLA matching. Methods We studied all 654 cadaveric kidney transplants performed in our center between 1983 and 1996 that had survived for more than six months. Eighty-two transplants, lost because of chronic rejection, were used as the outcome variable. The influence of HLA mismatches and shares on long-term graft survival was evaluated at the level of private antigens and cross-reactive groups (CREG) of MHC class I. HLA and other recipient, donor and transplant parameters were studied using univariate and multivariate Cox regression analysis.
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Patients and immunosuppression
654 cadaveric renal transplants done in the Leiden University Medical Center between January 1983 and July 1996 that had survived at least 6 months were included in the study. There were 106 repeat transplants. Patients were followed until death, return to dialysis, or until July 1, 1998. The median follow-up was 74 months (range, 6 to 186 months). Kidneys were allocated according to the matching algorithm used by Eurotransplant. In our center, we aimed for no more than 2 HLA mismatches and, preferably, no DR mismatches. The standard immunosuppressive regimen consisted of prednisone and cyclosporine (Sandimmune). Fifty-four patients (8.3%) were initially treated with prednisone and azathioprine. Sixty patients (9.2%) in the study were converted to azathioprine at 3 months posttransplant as part of a prospective Graft loss from chronic rejection is the major obstacle to successful long-term outcome following renal transplantation and results in an increasing number of patients on dialysis who are awaiting a repeat transplant. Both alloantigen-dependent and -independent factors have been identified that contribute interactively to the deterioration of graft function and structure that ultimately results in graft loss (1, 2) . A high donor age is the best recognized antigen-independent factor that affects graft survival adversely (3, 4) whereas the acute rejection history is the most important immunological predictor for late graft loss (5, 6) . Specifically, the number of acute rejection episodes, their timing, their severity and their histological type seem to be important (7) (8) (9) (10) (11) (12) (13) . The influence of HLA matching on long-term survival is less clear. The detrimental effect of HLA-disparity between donor and recipient as observed in large registries (4, (14) (15) (16) (17) has not been found in most single center studies (18, 19) . Matching for split HLA antigens has been reported to result in a better transplant outcome than matching for broad HLA antigens (20) , but this does not seem practical to implement because of the enormous polymorphism of the HLA system. Recently, it has been suggested that matching for the public HLA epitopes of MHC class I, also called crossreactive groups (CREG), increases the likelihood of recipients to obtain histocompatible kidneys (21, 22) . However,randomized trial (25) ; another 51 patients (7.8%) were converted in the first six months posttransplant from cyclosporine to azathioprine for clinical reasons, mostly because of suspected cyclosporine toxicity. Beyond three months posttransplant, the oncedaily cyclosporine dose was adjusted to a desired 24-hour trough concentration between 250 and 500 µg/l (polyclonal radioimmunoassay, Sandoz) and from 1989 onwards to a range of 50-150 µg/l (monoclonal radioimmunoassay, Incstar). During the first six months acute rejection episodes occurred in 56% of the cases and these were confirmed by biopsies in 88%. Interstitial rejection was diagnosed when tubulitis with a widespread interstitial infiltrate was present; a diagnosis of vascular rejection was made when arteritis was present. Rejection episodes were treated according to a standard protocol consisting of 3 one-gram intravenous doses of methylprednisolone, a 10-day course of anti-thymocyte globulin at a dose of 5 mg/kg guided by absolute lymphocyte counts, or a course of methylprednisolone for the first, second or third rejection episode, respectively.
Study design
Graft loss from chronic rejection was defined as graft failure beyond six months and exclusion of other obvious causes of graft loss. Therefore, analysis was censored for graft loss from recurrent or de novo glomerulonephritis, transplant renal artery stenosis or thrombosis, acute rejection as result of discontinuation of immunosuppressive drugs or patient death with a functioning graft (26) . Furthermore, we reviewed all biopsies and nephrectomy specimens obtained beyond the first six months from patients with late graft loss. Graft histology was evaluated according the recently published Banff '97 classification (27) A number of recipient, donor and transplant related characteristics were evaluated as risk factors of late graft loss. The following recipient variables were tested: age, original disease, cigarette smoking, pretransplant blood pressure, peak and current panel reactive antibodies defined by % PRA. The original diseases were grouped according to the UNOS report in inherited (polycystic disease, Alport's disease, dysplasia), glomerular (primary glomerulonephritis) and systemic (nephrosclerosis, diabetes mellitus, vasculitis, systemic lupus) diseases (4). Donor variables studied were age and cause of death. Transplant parameters studied included: year of transplant, repeat transplant, gender match, cold ischemic time, delayed graft function defined as the need of dialysis in the first week, and the baseline immunosuppressive drug regimen. All kidney donors and recipients were typed using the standardized Eurotransplant serum set for HLA -A,-B and -DR antigens. All donors were retyped at the Eurotransplant Reference Laboratory (28) . MHC class I antigens were assigned to one or more CREG (table 1) based on the amino acid residue system proposed for UNOS allocation (21) . We studied the impact of HLA matching of broad antigens as well as antigenic splits and crossreactive antigens (CREG). Not only was the degree of mismatching between donor and recipient studied but also the effect of sharing HLA antigens. The term 'shares' was used for the number of corresponding HLA antigens between donor and recipient. We made crosstabulations of HLA mismatches and shares to investigate their relationship. Furthermore, we compared the percentage of homozygosity between donors and recipients. We also evaluated risk factors observed up to 6 months posttransplant. Clinical and histological acute rejection parameters were studied in detail: number of acute rejection treatments in the first six months, time to the first and last acute rejection episode and histological type of rejection. The occurrence of an acute rejection episode beyond six months posttransplant was studied as a time dependent variable. CMV serology was routinely performed pretransplant and on clinical indication after transplantation. The occurrence of CMV seroconversion in the first six months was analyzed as a risk factor. As a result of the randomized and clinical conversion from cyclosporine to azathioprine in many patients, maintenance drug regimen at six months posttransplant was studied as a separate variable. The effect of cyclosporine trough levels could not be evaluated because of the mentioned change in assays in 1989. Therefore, we used the drug dose (mg/kg) at six months as a measure in patients on cyclosporine. Blood pressure, number of antihypertensive drugs, dipstick proteinuria, serum creatinine and endogenous creatinine clearance at six months were evaluated as clinical parameters.
Statistical analysis
A crosstabs procedure and a chi-square test tested the relationship between HLA mismatches and shares. Late graft loss from chronic rejection was used as the outcome variable. We used the Cox proportional hazard model to assess the predictive value of the studied risk factors. The effect of acute rejection episodes occurring after six months was tested as a time dependent variable. Significant predictors (P<0.05) of late graft loss in univariate analysis were fitted into a multivariate model. Other potential confounders such as prior graft loss, panel reactive antibodies delayed graft function and HLA mismatches were also added to the analysis. Forward selection techniques were used to choose significant risk factors. The histological type of acute rejection was used as rejection factor and serum creatinine >150 µmol/l as renal function parameter. Multivariate analysis was performed with and without inclusion of the serum creatinine concentration at six months into the model. We used the SPSS software package (8.0) for all our analyses.
Results
The demographic and clinical characteristics for the entire study population are presented in table 2. A total of 224 transplants were lost; 14 (6%) due to de novo or recurrent glomerulonephritis, 9 (4%) due to thrombosis or stenosis of the transplant renal artery, 3 (1%) due to discontinuation of immunosuppressive drugs, and 116 (52%) due to patient death with a functioning graft. After censoring for these causes late graft loss occurred in 82 (37%) transplants; in 62 cases graft histology was available from biopsies or nephrectomy specimens, which showed chronic allograft nephropathy in all cases. Concomitant borderline or acute rejection was present in 18 and 25 cases, respectively. The median follow up in the 82 lost transplants was 34 months (range, 6 to 132 months). Our cohort of patients studied was well matched for HLA antigens. The mean number of CREG and HLA-A,-B,-DR mismatches was 1.1 and 1.9, respectively. Crosstabulation of mismatches and shares revealed that mismatches and shares had a non-reciprocal relationship (table 3) . The mean number of CREG and HLA-A,-B,-DR shares was 4.5 and 3.6. The percentage of homozygosity was higher in the donors compared with the recipients; A locus: 21 versus 17%, B locus: 12 versus 9% and DR locus: 20 versus 14%. The quantitative impact of HLA matching on graft loss is shown in Table 4 . Although a higher number of HLA mismatches did not predict graft loss, sharing broad HLA-A,-B,-DR antigens had a beneficial effect on long-term outcome. Matching at the level of split antigens showed similar results. Sharing of HLA-DR antigens did not impact on outcome whereas the effect of sharing of HLA-A,-B antigens was almost significant. However, sharing CREG of MHC class I improved outcome significantly (figure 1). The univariate effects of the various other risk factors are shown in table 5. The relative risk of graft loss was increased in recipients younger than 50 years.
Pretransplant blood pressure was not significantly associated with graft failure. Patients with inherited renal diseases did better than patients with glomerular or systemic diseases. Cigarette smoking had a detrimental effect on graft outcome. Grafts from older donors (over age 50) experienced decreased graft survival. There was no difference between donors who died from cardiovascular causes or as a result of a trauma. The gender mismatch factor was not associated with an effect on graft loss. Patients who were on an initial immunosuppressive drug regimen not containing cyclosporine did worse compared with patients treated with cyclosporine. No significant long-term effect was found of the degree of sensitization, duration of cold ischemic time or delayed graft function. Also, first and repeat transplants had an equivalent outcome. Transplants performed in the first five years of the study period were more at risk for graft loss compared with the transplants done more recently. We found a strong influence of acute rejection on long-term graft survival. The occurrence of interstitial and especially vascular rejection within six months was associated with poor outcome ( figure 2 ). An increasing number and a later occurrence of rejection episodes were also associated with graft loss. Acute rejection beyond six months, tested as a time dependent variable, had a strong adverse effect on graft survival. Patients showing CMV seroconversion, presumably due to a CMV positive donor, had comparable results as patients with persistent negative CMV serology. The need of antihypertensive drugs, dipstick proteinuria and an elevated serum creatinine concentration (>150 µmol/l) at six months post-transplant were also associated with a higher risk of graft loss. The result of the multivariate analysis is given in Table 6 . It shows that recipients younger than 50 years were at risk for late graft loss. Recipients with an inherited original disease had a favorable outcome. The detrimental effect of grafts from donors older than 50 years was only present after discarding renal function at six months from the model. Sharing less than four CREG and a baseline immunosuppressive regimen consisting of prednisone and azathioprine predicted late graft loss independent from acute rejection. The negative effect of acute rejection on outcome was especially present in case of vascular rejection. Proteinuria and renal dysfunction at 6 months were independent clinical factors. 
Discussion
The aim of this study was to identify risk factors predicting late graft loss in renal transplant patients. We found that a higher number of HLA mismatches did not predict graft loss whereas sharing of HLA antigens, especially MHC class I CREG had a beneficial effect on long-term outcome. In contrast to North-American databases, our cohort of patients was very well matched. Therefore, it is not surprising that the mismatch level did not further affect long-term survival. Even when HLA antigenic splits were considered in the evaluation, outcome did not correlate with the degree of mismatching. However, we clearly demonstrated that HLA mismatches and shares had a non-reciprocal relationship. This phenomenon is explained by homozygosity of HLA specificities and the allocation algorithm aiming at a low number of mismatches and was confirmed by a higher percentage of homozygosity of the different HLA Time post-transplant, years loci in the donors. This finding is important because a significant long-term beneficial effect of histocompatibility was only apparent in the analyses of shared HLA antigens. The beneficial effect of sharing HLA antigens has been reported (29, 30) and is illustrated by the excellent survival of six-antigen shared grafts (31) . However, the difference between shares and mismatches with respect to their effect on graft survival has not been demonstrated previously in the same study population. HLA-A and -B matching seems to have a more profound effect on long-term survival compared to HLA-DR matching (32, 33) . Private class I antigens share antigenic determinants which can be assigned in public groups, also called CREG (21, 22, 29, 34, 35 ). We found a beneficial effect of sharing CREG on long-term graft survival that was independent from acute rejection in the multivariate analysis. A minimum of four shared CREG seems to be required for optimal graft survival. This result extends a recent report that showed that CREG matching was associated with a reduced frequency of late rejection episodes and improved 2-year graft function (23) . It has been suggested that self-restricted recognition of donor derived HLA peptides contributes to the pathogenesis of chronic rejection (36, 37) . Both mismatches and shares might play a role in this indirect allorecognition pathway. A low number of mismatches reduces the number of foreign peptides presented. Shared HLA antigens might result in downregulation or clonal deletion of T cells directed to these peptides. Prospective studies should reveal whether allocation algorithms based on CREG matching would reduce the number of failed grafts. Recipient, donor and transplant related factors all influenced outcome. After censoring for death with a functioning graft, recipients younger than 50 years were more likely to have late graft loss compared with older recipients (26) . This observation is consistent with other studies that have shown that young age is associated with a state of heightened immune responsiveness to alloantigens (38) . Moreover, young patients tend to have a lower compliance with prescribed drugs (39) . Another important factor in late graft loss is the age of the donor. The use of kidneys from older donors is correlated with an increased risk of late graft loss. Donor age influences the initial renal function and possibly also the quality of the tissue (40) . The detrimental effect of a higher donor age appears to be mediated by a decreased renal mass, as suggested by our observation that this risk was independent only after discarding renal function at six months from the multivariate model. Contrary to some earlier reports that showed no impact of smoking (41) , in the current study smoking significantly increased the risk of graft loss. Interestingly, smoking is also an emerging risk factor in other, non-transplant renal diseases (42) . Patients with inherited renal diseases such as polycystic disease did better than patients with systemic or glomerular disease, which is in agreement with large registry data (4). From our study it appears that the occurrence of late graft loss decreases over the long course of the study period. Indeed, patients receiving azathioprine as the baseline immunosuppressive regimen did worse than patients on a cyclosporine-based regimen did. These findings might be partially explained by the higher incidence of vascular rejection in the azathioprine treated patients (9) . On the other hand, conversion from cyclosporine to azathioprine in the first six months is safe (25) . We could not demonstrate an effect on late graft failure of pretransplant sensitization to lymphocyte antigens, ischemic damage and repeat transplantation. These variables are probably more related to early graft loss, with little effect on long-term survival (15, 43) . At six months posttransplant pending graft loss could be independently predicted by the histological pattern of previous acute rejection episodes, confirming previous data from our center and others that vascular rejection is a strong risk factor for late graft loss (9, 44) . The incidence of vascular rejection should be a valuable shortterm endpoint in clinical trials comparing different immunosuppressive regimens. Patients with multiple and late acute rejection episodes also showed an increased risk for late graft loss, as shown previously (7, 8, 10, 11, 13) . Proteinuria is not only an important prognostic factor of outcome (45) , it may also play a role in the pathogenesis of renal injury (46) . Maneuvers to reduce proteinuria may stabilize deteriorating graft function and may ultimately affect prognosis (47) . The serum creatinine concentration at 6 months was strongly correlated with subsequent graft loss. Although there is no direct clinical test to diagnose chronic rejection, the gradual deterioration in graft structure and function as a result of antigen-dependent mechanisms, it seems to constitute the predominant cause of late graft loss in our study population. We studied only patients with graft survival beyond six months, a point in time at which most graft failures from acute rejection have occurred. Chronic rejection was diagnosed by exclusion of graft failure as result of recurrent glomerulonephritis and patient death with a functioning graft albeit that graft loss due to cyclosporine toxicity is not completely excluded. However, most patients were treated with once daily Sandimmune, aimed at 24-hour trough levels between 50 and 150 µg/l (25). Furthermore, cyclosporine nephrotoxicity has not been reported as major cause of graft loss (48) . Moreover, biopsies and nephrectomy specimens obtained beyond six months posttransplant confirmed the presence of chronic allograft nephropathy. The concomitant histological presence of borderline or acute rejection supports ongoing rejection activity for the most part of the patients. Finally, antigendependent risk factors seem to play a dominant role in our study and resemble the established correlates of biopsy confirmed chronic rejection (40, (49) (50) (51) . We identified several coexisting recipient, donor and transplant related risk factors
